Premium
Effects of Selective Serotonin Reuptake Inhibitor Therapy on Endothelial Function and Inflammatory Markers in Patients With Coronary Heart Disease
Author(s) -
Pizzi C,
Mancini S,
Angeloni L,
Fontana F,
Manzoli L,
Costa GM
Publication year - 2009
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2009.121
Subject(s) - sertraline , placebo , medicine , serotonin reuptake inhibitor , depression (economics) , reuptake inhibitor , fluoxetine , c reactive protein , beck depression inventory , cardiology , gastroenterology , serotonin , inflammation , antidepressant , psychiatry , anxiety , pathology , alternative medicine , receptor , macroeconomics , hippocampus , economics
We investigated the effect of sertraline on inflammation and endothelial function in patients with coronary heart disease (CHD) and symptoms of depression. One hundred patients with CHD and depression were randomized in a double‐blind fashion to receive sertraline or a placebo. We measured symptoms of depression (Beck Depression Inventory (BDI) score), levels of inflammatory markers (C‐reactive protein (CRP) and interleukin‐6 (IL‐6)), and flow‐dependent endothelium‐mediated dilation (FMD) before and after 20 weeks of treatment. Sertraline treatment significantly reduced the BDI score as compared with both baseline and placebo. Levels of CRP and IL‐6 also decreased after 20 weeks of sertraline treatment, whereas they did not significantly change in the placebo group. There was a significant improvement in FMD in patients on sertraline treatment, whereas there was no change in FMD in the placebo group. Sertraline improves endothelial function and reduces inflammatory markers in patients with CHD and symptoms of depression. Clinical Pharmacology & Therapeutics (2009) 86 5, 527–532. doi: 10.1038/clpt.2009.121